AKTS
Aktis Oncology, Inc.
There isn't enough reported data to score AKTS yet.
AKTS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
AKTS's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
AKTS PE Valuation
AKTS has no meaningful PE right now: it lost money over the past year.
AKTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect AKTS's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
AKTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.64 | -$0.64 |
AKTS lost $1.64 per share over the past year, a bigger loss than the year before.
AKTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.9M | +147% |
| Q2 2026 | $3.4M | +111% |
| Q1 2026 | $3.2M | +123% |
| Q4 2025 | $1.9M | +100% |
AKTS's revenue has grown year over year every quarter since late 2025: $4M last quarter, up 147% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -890% | +263 points |
| Q2 2026 | -854% | +455 points |
| Q1 2026 | -704% | +550 points |
| Q4 2025 | -929% | +747 points |
| Q3 2025 | -1153% | N/A |
| Q2 2025 | -1309% | N/A |
| Q1 2025 | -1254% | N/A |
| Q4 2024 | -1676% | N/A |
AKTS's operating margin was −890% last quarter, up 263 points from the same quarter a year ago.
AKTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.8M | -$9.6M |
| Q2 2026 | -$21.8M | -$4.1M |
| Q1 2026 | -$26.1M | -$6.7M |
| Q4 2025 | -$19.4M | -$4.4M |
AKTS has burned cash in almost every quarter: −$94M over the past year, against −$69M the year before.
AKTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +349K shares |
| 1 year | +6% | +3.1M shares |
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
AKTS Net Leverage
AKTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AKTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 13.0 | Oversold |
AKTS's weekly RSI is 36 (neutral) and its Stochastic is 13 (oversold).
AKTS PE vs Healthcare Sector
AKTS has no meaningful PE right now: it lost money over the past year.
AKTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.9 | 3.5% below |
| 20 week MA | $21.8 | 25% below |
AKTS is in a downtrend: it's below all two of its weekly moving averages, and 25% below its 20-week average.
AKTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $22.4 | $16.3 | -27% |
It's down 27% so far in 2026.